A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

Albiruni R. Abdul Razak, Wilson H. Miller, Geoffrey L. Uy, Steven Blotner, Anne Marie Young, Brian Higgins, Lin Chi Chen, Lia Gore

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint Dive into the research topics of 'A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences